Can Bondlido convert its post-approval sales agreement and launch into actual sales?

Bondlido obtained marketing approval from the FDA in September 2025 for postherpetic neuralgia in adults and has reached the development-completed stage. Revenue in FY2026-H1 was ¥11.725 million, comprising ¥6.851 million in product sales and ¥4.874 million in R&D and other revenue. As this is the first full-scale commercialization phase following approval, whether product sales have increased from ¥6.851 million on a cumulative third-quarter basis will be the first numerical indicator of the effectiveness of the launch preparations.

As of FY2026-H1, the company said it had signed legally binding term sheets covering the basic terms of a sales partnership with Terrain Pharmaceuticals in May 2026 and was proceeding with launch preparations while finalizing the details of the sales license agreement. The plan called for the sales license agreement to be signed in August 2026 and the product to launch in the fourth quarter. Subsequent related reporting dated 30 October said that a sales partnership with Terrain had been concluded, but the published summary did not confirm the final agreement’s economic terms or a specific launch date.

Accordingly, at the next earnings release it will be necessary to distinguish not only whether the partnership event occurred, but also whether the sales license agreement moved from the term sheet to a final agreement, whether there was an upfront payment or revenue recognition when sales began, and whether initial deliveries and shipments were completed. Full-year revenue guidance was ¥385 million as of FY2026-H1. Compared with H1 revenue of ¥11.725 million, this plan assumes a substantial revenue contribution in the second half. If Bondlido product sales had not begun by the third quarter, achievement of the full-year forecast would depend heavily on the launch timing in the fourth quarter.